Company Description
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases.
The company operates through Cell Therapy, Degenerative Disease, and BioBanking segments. Its lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn’s disease.
In addition, the company is developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis.
Celularity Inc. produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand.
The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates.
Celularity Inc. was founded in 1998 and is based in Florham Park, New Jersey.
| Country | United States |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 120 |
| CEO | Robert Hariri |
Contact Details
Address: 170 Park Avenue Florham Park, New Jersey 07932 United States | |
| Phone | 908 768 2170 |
| Website | celularity.com |
Stock Details
| Ticker Symbol | CELU |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001752828 |
| CUSIP Number | 151190105 |
| ISIN Number | US1511902041 |
| Employer ID | 83-1702591 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Robert Joseph Hariri M.D., Ph.D. | Founder, Chief Executive Officer and Chairman |
| John R. Haines | Senior EVice President, Global Manager and Chief Administrative Officer |
| David C. Beers C.F.A. | Chief Financial Officer |
| Carlos Ramirez | SVice President of Investor Relations |
| Kyle Harold Fletcher Esq. | Executive Vice President, General Counsel and Chief Compliance Officer |
| Dr. Stephen A. Brigido D.P.M. | President of Degenerative Diseases |
| Sharmila Koppisetti M.D. | Senior Vice President of Clinical Dev. Immunology and Drug Safety |
| Tim Wilk | Senior Vice President of Technical Operations |
| David Jakob Lemus CPA, M.S., MBA | Treasurer |
| Timothy Smith | Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 19, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 15, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Nov 8, 2024 | 8-K | Current Report |
| Nov 7, 2024 | 8-K | Current Report |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Oct 25, 2024 | 8-K | Current Report |
| Oct 21, 2024 | 8-K | Current Report |
| Oct 16, 2024 | 10-Q | Quarterly Report |
| Oct 16, 2024 | 8-K | Current Report |
| Sep 13, 2024 | 8-K | Current Report |